Profile

Dajing Xia, M.D., Ph.D.
Professor
Institute of Immunology
Zhejiang University School of Medicine
388 Yu Hang Tang Lu
310058 Hangzhou, China
Tel: +86 (0) 571 8820 8284
email: dxia@zju.edu.cn

SCIENTIFIC CAREER
2007.12- Professor, Institute of Immunology,Zhejiang University School of Medicine Hangzhou

2008.08-2008.12 Visiting Professor, Loma Linda University Medicine center, Loma Linda, CA, USA

2002.10-2007．12 Associate Professor, Institute of Immunology，Zhejiang University School of Medicine

2006.01-2006.04 Research scholar (Research Fellow), Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, SK, S7N 4H4, Canada

2004.01-2005.06 Research scholar (Postdoctoral fellow), Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, SK, S7N 4H4, Canada

1995.10-2002.10 Lecturer, Institute of Immunology, Zhejiang University School of Medicine

1990.08-1995.10 Research assistant, Medical school of Zhejiang University,Hangzhou, China


EDUCATION
1999-2002 Ph.D Cancer Institute, Zhejiang University School of Medicine

1994-1998 M.Sc Institute of Immunology, Zhejiang University School of Medicine

1985-1990 M.D Department of Medical Nutrition, Zhejiang Medical University


Membership in Scientific Societies
2002- Chinese Society of Immunology
2000- Chinese Medical Association Zhejiang Branch

Grants（as PI)
2007-2012 National Key Basic Research Program of China (973，2007CB512807), topic: The regulation to innate immunity in fulminant hepatitis mice by Gr-1+CD11b+ Myeloid Suppressor Cells, Amount: 1000,000RMB
2008-2010 Excellent Youth Foundation of Zhejiang Provincial Natural Foundation (R207433), XIA Dajing’s Research Group, Amount: 300,000RMB
2005-2007 National Natural Science Foundation of China (NSFC, 30471588), topic: The role of a novel inhibitory immunoreceptor DIgR2 in immunological regulation and its related mechanism, Amount: 210,000RMB
2005-2007 Canadian Institute of Health Research (CHIR) -RPP Postdoctor Award, topic: Stimulation of CD8+ cytotoxic T lymphocyte response by CD4+ T helper cells through acquired MHC and co-stimulatory molecules from APC, Amount: 90,000CA$
2004-2006 Initial research foundation for homecoming scientists from Chinese Ministry of Education(419151-G50701), topic: Research on the function of breast cancer associated growth inhibitor BDGI, Amount: 20,000RMB
2003-2005 National Natural Science Foundation of China (NSFC, 30200334), topic: Molecular cloning, characterization of a novel breast cancer associated growth inhibitor BDGI, Amount: 220,000RMB


PUBLICATIONS

I Publication in English Journals and books:
(A) Articles published or accepted in referred journals:
1.Wang Q, Li H, Yao Y, Xia D, Zhou J. The overexpression of heparin-binding epidermal growth factor is responsible for th17-induced airway remodeling in an experimental asthma model. J Immunol. 2010;185(2):834-841.
2.Huang C, Zhao J, Li Z, Li D, Xia D, Wang Q, Jin H. Multi-chaperone-peptide-rich mixture from colo-carcinoma cells elicits potent anticancer immunity. Cancer Epidemiol. 2010;34(4):494-500.
3.Xu G, Wang L, Chen W, Xue F, Bai X, Liang L, Shen X, Zhang M, Xia D, Liang T. Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation. Liver Transpl. 2010;16(3):357-63.
4.Zhang M, Han Y, Han C, Xu S, Bao Y, Chen Z, Gu Y, Xia D, Cao X. The beta2 integrin CD11b attenuates polyinosinic: polycytidylic acid-induced hepatitis by negatively regulating natural killer cell functions. Hepatology. 2009; 50(5):1606-16.
5.Xia S, Guo Z, Yao Y, Xu X, Yi H, Xia D, Cao X. Liver stroma enhances activation of TLR3-triggered NK cells through fibronectin. Mol Immunol. 2008;45(10):2831-8.
6.*Shi L, *Luo K, *Xia D, Chen T, Chen G, Jiang Y, Li N, Cao X. DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood. 2006;108(8):2678-86 (*sharing the first authorship)
7.Xia D, Hao S, Xiang J. CD8+ Tc-APC stimulate central memory CD8+ T cell responses via acquired pMHC I complexes and CD80 costimulation and IL-2 secretion. J Immunol. 2006;177(5):2976-84.
8.Xia D, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cells vaccine in combating well-established tumors. Cell Research. 2006, 16(3): 241-59.
9.Wang T*, Xia D*, Li N*, Wang C, Chen T, Wan T, Chen G, Cao X. Bone marrow stromal cell-derived growth inhibitor, BDGI, inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis. J Biol Chem. 2005; 280(6):4374-82 (*sharing the first authorship)
10.Wu Q, Xia D, Carlsen S, Xiang J. Adenovirus-mediated Transgene- engineered Dendritic Cell Vaccine of Cancer. Current Gene Ther. 2005;5(2):237-47.
11.Chen Z, Xia D, Bi X, Saxena A, Sidhu N, El-Gayed A, Xiang J. Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. J Gene Med. 2005;7(4):506-17.
12.Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, Zhang L, Yu H, Cao X. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8 (+) CTL response. J Cancer Res Clin Oncol. 2005;131(7):468-78.
13.Xia D, Li F, Jim Xiang. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radiopharm. 2004; 19(3): 322-330
14.Liu Y, Xia D, Li F, Zheng C, Xiang J. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther. 2004; 12(2):122-32.
15.Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, Zhang L, Yu H, Liu Y, Cao X. Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett. 2004; 94(1-2):141-151.
16.Wang B, Li N, Sui L, Wu Y, Wang X, Wang Q, Xia D, Wan T, Cao X. uBMSC-MCP, a novel member of mitochondrial carrier superfamily, enhances dendritic cell endocytosis. Biochem Biophys Res Commun. 2004; 314(1): 292-300.
17.Huang C, Yu H, Wang Q, Ma W, Xia D, Yi P, Zhang L, Cao X. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci. 2004; 95(2):160-7.
18.Jiang Y, Wan T, Chen G, Xiu F, Xia D, Zhang W, Zhou X, Cao X. DC-CLM, a cadherin-like molecule cloned from human dendritic cells, inhibits growth of breast cancer cells. J Cancer Res Clin Oncol. 2003; 129(1):57-64.
19.Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. J Mol Med. 2003; 81(9):585-596.
20.Xia DJ, Zhang WP, Zheng S, Wang J, Pan JP, Wang Q, Zhang LH, Hamada H, Cao X. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther 2002; 9 (9): 592-601.
21.Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. J Mol Med 2002;80(9):585-594
22.Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X.Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response. J Cancer Res Clin Oncol 2001;127(12):718-726.
23.Pan J, Ju D, Wang Q, Zhang M, Xia D, Zhang L, Yu H, Cao X. Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway. Immunol Lett 2001;76(3):153-61.
24.Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X.Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Gene Ther 2001;8(7):542-550.
25.Zhang LH, Pan JP, Yao HP, Sun WJ, Xia DJ, Wang QQ, He L, Wang J, Cao X. Intrasplenic transplantation of IL-18 gene-modified hepatocytes: an effective approach to reverse hepatic fibrosis in schistosomiasis through induction of dominant Th1 response. Gene Ther 2001;8(17):1333-1342.
(B) Abstract:
Yao HP, Xia DJ, Zhang L. Serum levels of sfas, sICAM-1, IL-18 in chronic hepatitia C patients and clinical significance. J Gastroenterology and Hepatology 2001(5); 16(s): A279.
(C) Book chapter:
Xia D, Chan T, Xiang J. Dendritic cell/Myeloma Hybrid Vaccine. In Molecular Medicine (ed. Brown R), Humana, Totowa, NJ, pp223-231, 2005
II Publication in Chinese Journals (with English Abstract) or books:
(A) Articles published or accepted in referred journals:
1.Wang C, Wu D, Liu J, Xia D (corresponding author). Promoting effect of NK cells induced by myeloid-derived suppressor cells in acute fulminate hepatitis of mice. Journal of Zhejiang University (Medical Sciences). 2010; 39(4):357-363.
2.Wu D, Xia D (corresponding author). Research progress on myeloid-derived suppressor cells in infective diseases. INT J EPIDEMIOL INFECT DIS. 2008;35(6):368-372.
3.Zhang J, Xia DJ (corresponding author). Th17 and autoimmune diseases. Int J Immunol. 2008;31(6):411-415.
4.Ye Y, Xia DJ (corresponding author). Toll-like receptors and the innate immunity and adaptive immunity mediated by dendritic cells. Chin J Cell Biol. 2007, 29(5):637-640.
5.Wu W, Wang JL, Xia DJ(corresponding author). Mechanisms of suppression by CD4+CD25+ regulatory T cells in Type I Diabetes．Chin J Immunol, 2007, 23(2): 89-93.
6.Wang J, Zhou Z, Xia DJ (corresponding author). Study on the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100 enhanced by Lentinan and its related mechanisms. Chinese Journal of Integrated Traditional and Western Medicine (CJITWM). 2007, 27(1): 60-64.
7.Yuan H, Cao X, Xia DJ (corresponding author). CD4+CD25+ regulatory T cells in HIV infection．Inter J Epidemiol Infect Dis, 2006, 33(2): 83-86.
8.Xia DJ, Wang JL. Viral vectors and dendritic cell-based gene therapy of cancer. Acad J Sec Mil Med Univ 2002; 23(10): 1075-1079.
9.Yao HP, Li M, Zhang L, Wang QQ, Xia DJ. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human reheumatoid synovial fibroblasts. Chin J Lab Med, 2002, 25(6): 345-348.
10.Yao HP, Xia DJ, Zhang L. Serum levels of sfas, sICAM-1, IL-18 in chronic hepatitia C patients and clinical significance. Journal of Zhejiang University (Medical Science), 2002, 31(1):2-5.
11.Xia DJ, Wang J, Shao CS, Shen J, Bao JF. Study on the antitumor activity of cord blood mononuclear cells (CBMC) activated by interleukin-12 alone or in combination with interleukin-2. Chin J Hematol, 2000, 21(1): 30-33.
12.Bao JF, Xia DJ, Shao CS. Comparison of the methods for separating hematopoietic stem cells form umbilical cord blood. Journal of Zhejiang Medical University, 1999, 28(3): 114-116.
13.Xia DJ, Bao JF, Shen J, Shao CS. The Effect on proliferation of human peripheral blood mononuclear (PBMC) and its antitumor activity by IL-12 combined with low-dose IL-2. Journal of Zhejiang University (Medical Science), 1999, 28(6): 248-252.
14.Zhang AZ, Xia DJ, Zhu SM. The analysis of the diabetic recipes. Journal of Behavior Medicine, 1998, 4: 62-65.
15.Huang SX, Xia DJ, Zhu SM. The evaluation of three major nutriments in recipes of diabetes mellitus patients. Journal of Practical Nutrition. 1997, 1: 30-33.
(B) Book chapters:
1.Xia D. Hypersensitivity & Autoimmune and Autoimmune Disease. In Medical Immunology and Microbiology. (editors: Zhang LF, Zhang LH), People Health Press. Pages: 105-120, 121-130, Feb. 2007.
2.Xia D. Lymphocytes & Antigen Presenting Cells and other Immunocytes. In Medical Immunology. (editors: Pan J, Shao CS), Zhejiang University Press. Pages: 131-161, Aug. 2006.
3.Xia D. Complement & Application of Immunology. In Medical Immunology. (editors: Shao CS, Xia D), Zhejiang University Press. Pages: 22-30; 141-148, June. 2003.
4.Xia D. Immunodeficiency Disease. In Clinical Diseases and Immunology. (ed: Shao cs) Science Press of P.R. China, Pages: 45-57, Jan. 2002.